Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/55375
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGhosh, Shatabdi-
dc.contributor.authorDey, Sanjit-
dc.contributor.authorGhosh, Sujoy-
dc.date.accessioned2020-09-30T05:55:50Z-
dc.date.available2020-09-30T05:55:50Z-
dc.date.issued2020-10-
dc.identifier.issn0975-0959 (Online); 0301-1208 (Print)-
dc.identifier.urihttp://nopr.niscair.res.in/handle/123456789/55375-
dc.description512-520en_US
dc.description.abstractInteractions of current pandemic COVID-19 and pre-existing major health burden Diabetes Mellitus have posed a serious global public health crisis. The emergence of COVID-19 as a communicable viral infection along with the presence of non-communicable diabetes, have transformed the health system into a knife with two sharp ends. Though diabetes worldwide is almost 20 times more than COVID-19 positive cases, the severe virulence and pathogenesis coincides with the routine treatment and pathogenesis of diabetes making it one of the most serious comorbid factors. The first three deaths due to COVID-19 reported in China were diabetes patients. The severity of the association of diabetes with COVID-19 ranges from 5 to 20%. Type 1 diabetes mellitus and type 2 diabetes mellitus increase the susceptibility to infections and their complications. The present study was attempted to review probable interaction between these two global health burdens and possible suggestive management to control their detrimental effect. An intensive online search was conducted using two databases, PubMed and Google Scholar. Most hypothesized pathways for COVID-19 infection are the ACE2 receptors and RAAS system followed by the DPP4 receptor pathway. This review proposes that proper and timely management of the COVD-19 patients with diabetes comorbidity might reduce COVID-19 disease burden.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJBB Vol.57(5) [October 2020]en_US
dc.subjectType 1 Diabetes Mellitusen_US
dc.subjectType 2 Diabetes Mellitusen_US
dc.subjectACE2 receptorsen_US
dc.subjectDPP4 receptorsen_US
dc.subjectRAAS systemen_US
dc.subjectSARS-CoV-2en_US
dc.titleDiabetes in the time of COVID-19 pandemic: A knife with two sharp endsen_US
dc.typeArticleen_US
Appears in Collections:IJBB Vol.57(5) [October 2020]

Files in This Item:
File Description SizeFormat 
IJBB 57(5) 512-520.pdf448.83 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.